Abstract
Background:
Animal models focusing on neuromuscular outcomes are crucial for understanding the mechanisms of intensive care unit-acquired weakness (ICU-AW) and exploring potential innovative prevention and treatment strategies.
Aim:
To analyse and evaluate preclinical ICU-AW models.
Methods:
We manually searched five English and four Chinese databases from 1 January 2002, to 1 February 2024, and reviewed related study references. Full-text publications describing animal models of muscle weakness and atrophy in critical illness were included. Detailed information about model types, animal species, sex, age, induction methods, outcome measures, drawbacks and strengths was extracted from each included study.
Results:
A total of 3,451 citations were initially retrieved, with 84 studies included in the final analysis. The most frequently studied animal model included rodents (86.9%), 64.3% of which were male animals. ICU-AW animal models were mostly induced by comprehensive intensive care unit (ICU) interventions (38.1%) and sepsis (51.2%). Most studies focused on limb muscles (66.7%), diaphragm muscles (21.4%) or both (9.5%). Reported outcomes primarily included muscular pathological changes (83.3%), electrophysiological examinations of muscles (57.1%) and animal grip strength (16.6%). However, details such as animal age, mortality data, experimental design, randomisation, blinding, sample size and interventions for the experimental group and/or control group were inadequately reported.
Conclusion:
Many preclinical models are used to study ICU-AW, but the reporting of methodological details is often incomplete. Although current ICU animal models can mimic the characteristics of human ICU-AW, there is no standard model. Future preclinical studies should develop a standard ICU-AW animal model to enhance reproducibility and improve scientific rigor in exploring the mechanisms and potential treatment of ICU-AW.
Introduction
As the number of intensive care unit (ICU) survivors increases, ICU-acquired weakness (ICU-AW) has become a common neuromuscular complication (Kress and Hall, 2014), with an overall incidence rate of 48% (Fazzini et al., 2023). ICU-AW is characterised by the acute onset of generalised symmetrical muscle weakness affecting the extremities and respiratory muscles in critically ill patients. It typically develops following prolonged ICU stays and cannot be attributed to the original disease (Lad et al., 2020). This weakness is often accompanied by muscle wasting and manifests alone or in combination with polyneuropathy, myopathy and muscle atrophy (Piva et al., 2019; Gonzalez et al., 2022). ICU-AW has three subtypes: critical illness polyneuropathy (CIP), critical illness myopathy (CIM) and critical illness neuromyopathy (CINM). CIP involves the peripheral nervous system, CIM affects the muscles, and CINM involves both muscles and nerves (Intiso et al., 2022).
An ICU-AW diagnosis is based on clinical features, neurophysiological testing and nerve and muscle biopsies. Clinically, ICU-AW is characterised by symmetrical weakness with a Medical Research Council score <48. Neurophysiological testing can help differentiate the subtypes of ICU-AW. CIP is indicated by distal sensory loss, reduced compound muscle action potentials (CMAP) and sensory nerve action potentials (SNAP), with normal or near-normal nerve conduction velocities. CIM is identified by short-duration, low-amplitude motor unit potentials on electromyography (EMG), reduced CMAP on direct muscle stimulation and muscle biopsy showing atrophy with thick filament loss or necrosis (Sapra, 2021). CINM combines the characteristics of both CIP and CIM (Wieske et al., 2011).
ICU-AW lacks a discernible underlying cause other than the critical illness itself. It is often associated with the high severity of illness upon admission, sepsis and/or shock, multiple organ dysfunction syndrome (MODS), mechanical ventilation (MV), prolonged sedation and immobilisation, hyperglycaemia, corticosteroid use, neuromuscular blocking agent application and older age in patients (Elkalawy et al., 2023).
Muscle atrophy and loss of muscle function associated with critical illness contribute to difficulties in ventilation weaning, prolong mechanical duration, extend ICU and hospital stay, increase morbidity and mortality within and outside the hospital and even reduce long-term physical function and quality of life (Sapra, 2021). Therefore, understanding the pathogenesis of ICU-AW, particularly at the molecular level, is an urgent concern. This knowledge is crucial for developing future therapies to prevent ICU-AW and facilitate recovery (Lad et al., 2020).
However, the mechanisms underlying ICU-AW are intricate, involving functional and structural alterations in the muscles and nerves (Hermans, 2015). Muscle biopsy and muscle electrophysiological examination are two crucial components in exploring the pathogenesis and molecular mechanisms of critically ill patients experiencing ICU-AW. Nevertheless, the utilisation of these methods presents ethical challenges and is associated with several complications, including pain, bleeding and nerve damage. These conditions are caused by the invasive nature of the methods, which contributes to the difficulty of their implementation in clinical practice (Yoshihara et al., 2023).
In this context, the establishment of an appropriate animal model for ICU-AW is crucial to offer insights into the pathophysiology of muscular and neurological injuries during the development of ICU-AW (Guillon et al., 2019; Liu et al., 2023; Addinsall et al., 2022). However, the capacity of current models to accurately reflect the characteristics of muscular weakness and atrophy in ICU-AW and their ability to detect the effects of triggering on outcomes remain unclear.
This scoping review aims to comprehensively analyse and evaluate the characteristics of current animal models of ICU-AW as well as provide detailed methodologies and assessment of neuromuscular outcomes. Moreover, it seeks to analyse the advantages and disadvantages associated with each model type and recommend the most suitable model for future preclinical research based on clinical practice.
Materials and methods
This scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (Tricco et al., 2018). The review procedures, including literature retrieval, screening, selection, data extraction and summarisation, were independently carried out by two authors (YQM and SJM). Any disagreements were resolved through consensus or consultation with a third senior author (CSL).
Eligibility criteria
An ICU-AW animal model involves intentionally inducing the illness in animals to produce subsequent related muscular weakness and atrophy (Zou et al., 2018). The eligibility criteria encompass the following: (1) Population: all animal experimental models of ICU-AW or those investigating critical illness impacting muscular weakness and atrophy; (2) Intervention: any triggered intervention referring to clinical etiological factors inducing ICU-AW during the course of critical illness; (3) Controls: animals compared with the intervention group without triggered factors or other interventions or before-and-after controls; (4) Outcomes: any outcome associated with muscular weakness or atrophy; (5) Literature type: original research; and (6) Languages: English or Chinese.
The exclusion criteria are as follows: (1) research topic is unrelated to ICU-AW; (2) cell culture, human experimentation or use of baby animals; (3) target tissue is not muscle; (4) non-neuromuscular outcomes; (5) review or commentary articles and conference abstracts, and (6) studies with unavailable full text.
Search strategy
Given that ICU-AW was first studied in a clinical setting in 2002 (De Jonghe et al., 2002), our search period ranged from 1 January 2002, to 1 February 2024. The following databases were searched: Medline, PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP databases), SinoMed and Wanfang database. The search strategy was developed in collaboration with trained medical librarians and included keywords aligned with the inclusion criteria. Reference lists from relevant reviews and included studies were likewise checked. The detailed search strategy is presented in Supplementary Table S1.
Study selection and data extraction
The literature review and data synthesis were conducted in March 2024. EndNote X9 (Clarivate Analytics, Philadelphia, PA, United States) was employed for literature management and screening. After duplicate articles were removed, the titles and abstracts of the remaining literature were reviewed. Subsequently, the full text of potential studies was meticulously reviewed to decide the final inclusion.
In this study, ICU-AW models are defined as those in which certain methods are used to induce animals to mimic the complex clinical conditions of patients to research the pathogenesis of the ICU-AW and targets for intervention (Zou et al., 2018). A standardized data extraction form was developed following thorough discussions within our research team and was tested prior to the formal data collection. Extracted data encompassed authors, publication year and country, study objective and design, type of animal model, animal characteristics, induction of animal models, utilisation of life-supporting treatment, sample size, outcomes and time-point of outcome measurements, and drawbacks and strengths from each included study. The collected outcomes primarily included changes in muscle function, morphology, muscle atrophy markers, muscle electrophysiological measurements, body weight, muscle weight, muscle strength, mortality, behavioural changes and other relevant indicators. Categorical variables were presented as numbers and percentages. Continuity variables for abnormal distribution are expressed as median and their interquartile range.
Results
Selection process
A total of 3,451 citations were initially retrieved. Ultimately, 84 studies were included in this review, including three in Chinese. The detailed flow chart of study selection is displayed in Figure 1.
FIGURE 1
Characteristics of included studies
The characteristics of ICU-AW animal models are summarised in Supplementary Table S2. Nearly half of all publications (46.4%, n = 39/84) were released in the recent 5Â years. Studies were conducted across 13 countries, of which the top three original countries were the United States, China and Sweden (Table 1).
TABLE 1
| Variables | Total (n = 84) |
|---|---|
| Year of publication | |
|  2020–2023 | 31 (36.9%) |
|  2014–2019 | 31 (36.9%) |
|  2008–2013 | 17 (20.2%) |
|  2002–2007 | 5 (6.0%) |
| Original Country | |
|  USA | 20 (23.8%) |
|  China | 20 (23.8%) |
|  Sweden | 12 (14.3%) |
|  France | 7 (8.3%) |
|  Belgium | 5 (6.0%) |
|  Japan | 7 (8.3%) |
|  Germany | 4 (4.8%) |
|  Netherlands | 3 (3.6%) |
|  British | 2 (2.4%) |
|  Mexico | 1 (1.2%) |
|  Turkey | 1 (1.2%) |
|  Italy | 1 (1.2%) |
|  Jordan | 1 (1.2%) |
| Objective | |
|  Exploring mechanism | 51 (60.7%) |
|  Physical interventions | 6 (7.1%) |
|  Pharmaceutical or others interventions | 20 (23.8%) |
|  Developing ICU-AW animal model | 7 (8.3%) |
| Animal species | |
|  Mice | 38 (45.2%) |
|  Rats | 35 (41.7%) |
|  Pigs | 10 (11.9%) |
|  Rabbits | 1 (1.2%) |
| Sexs | |
|  Male | 54 (64.3%) |
|  Female | 15 (17.9%) |
|  Both | 3 (3.6%) |
| Animal age | |
|  Juvenile | 30 (35.7%) |
|  Adults | 25 (29.8%) |
|  Baby and elder | 1 (1.2%) |
| Target muscle | |
|  Diaphragm | 18 (21.4%) |
|  Limb muscle | 56 (66.7%) |
|  Diaphragm and limb muscle | 8 (9.5%) |
|  Masseter Muscle | 1 (1.2%) |
|  Masseter Muscle and limb muscle | 1 (1.2%) |
| Mortality reported | |
|  Yes | 36 (42.9%) |
|  No | 48 (57.1%) |
| Life-support treatment after induction | |
|  Yes | 60 (71.4%) |
|  No | 24 (28.6%) |
Characteristics of included studies.
Table 1 presents the characteristics of all included studies. The most common objective of the included studies was exploring ICU-AW pathogenesis (60.7%, n = 51/84). Rodents, primarily mice (45.2%, n = 38/84) and rats (41.7%, n = 35/84), were used, and the most common species were C57 BL/6 mice (39.3%,n = 33/84) and Sprague Dawley rats (26.2%, n = 22/84). Notably, 64.3% of the studies (n = 54/84) used male animals, and only 17.9% used female animals (n = 15/84). Only 56 studies (66.7%) described the animal age.
A total of 46.4% of the studies reported utilising randomised controlled trials (RCTs) (n = 39/84). However, none of these studies specified the exact methods of randomisation. Specifically, 4.8% did not specify the use of a control group (n = 4/84), and none reported blinding. Only one study estimated the sample size, which was described vaguely in 22 studies (26.2%). The median number of animals used in the remaining studies for the intervention group and the control group was 8 (Intiso et al., 2022; Yoshihara et al., 2023) and 8 (Intiso et al., 2022; Tricco et al., 2018), respectively.
Regarding model categorisation, sepsis models, comprising 51.2% of the total (n = 43/84), were predominantly induced by caecal ligation and perforation (CLP) (67.4%, n = 29/43), followed by intraperitoneal injection of lipopolysaccharides (LPS) (14.0%, n = 6/43) or Escherichia coli (4.7%, n = 2/43) (Figures 2A, B; Table 2). The second most common models were ICU models (38.1%, n = 32/84), which are those that replicate the complex clinical conditions of human ICU patients with multiple risk factors, including severe sepsis, immobilisation, MV, MODS, hyperglycaemia, denervation, steroids and/or neuromuscular blockade drug usage, and so on (Lad et al., 2020) (Figure 2D, Table 2). Most ICU models (78.1%, n = 25/32) were typically triggered by MV after deep anaesthesia or sedation, with or without other ICU-AW risk factors, such as neuromuscular blockers agent (NMBA), sepsis or corticosteroids (CS) and life support treatment and monitoring (Figure 2D1–2; Table 2). Other ICU models mostly included sepsis with immobilisation (15.6%, n = 5/32) (Figure 2D3; Table 2). Furthermore, 4.8% of the included studies were disuse models (n = 4/84; Figure 2C; Table 2).
FIGURE 2
TABLE 2
Characteristics of different ICU-AW animal models.
ARDS: acute respiratory distress syndrome; CLP: caecal ligation perforation; CS: corticosteroids; IP: intraperitoneal injection; IV: intravenous injection; IN: intranasal inoculation; LPS: lipopolysaccharide; NMBA: neuromuscular blocking agent;/: none; N: the number of outcomes.
Outcomes
The types of target muscles among the included studies are summarised in Table 1. Significant variations were observed in the intervention duration and time of outcome assessment among different models. For the sepsis model, sampling time ranged from 6 h to 61 days, with the most common occurring within 24 h 46.5% (n = 20/43). ICU models were typically sampled at 4 hours–4 days (68.8%, n = 22/32), 5–8 days (62.5%, n = 20/32) and 9–14 days (28.1%, n = 9/32) of post-intervention. Diaphragm muscle samples were typically collected within 24 h (69.2%, n = 18/26). For limb muscles, sampling occurred at various intervals: 6 hours–2 days (46.9%, n = 30/64), 3–4 days (32.8%, n = 21/64), 5–7 days (42.2%, n = 27/64) and more than 8 days (35.9%, n = 23/64) after induction. Notably, only 42.9% of the studies (n = 36/84) reported outcomes at more than two time points. Further details are provided in Supplementary Table S2.
Skeletal muscle weakness and atrophy are key features of ICU-AW (Wang et al., 2020). Muscle weakness was described in 27.4% (n = 23/84) of the studies, whereas muscle atrophy was noted in 25.0% (n = 21/84). Meanwhile, 39.3% of the studies (n = 33/84) focused on both muscle function decreasing and atrophy, with only 7 studies not demonstrating pathological changes in the ICU-AW model group. In addition, 42.9% of the studies (n = 36/84) evaluated the level of atrophy markers, and 20.2% (n = 17/84) reported changes in actin and/or myosin protein levels.
Sepsis animal models replicated muscle weakness in 27.9% of the studies, muscle atrophy in 23.3% and both in 39.5%. Four studies did not specify the presence of muscle weakness or atrophy. Only 9.3% reported changes in myosin and actin but without priority myosin lost. By contrast, ICU models induced by MV with other factors showed muscle weakness in 28.1% of the studies, muscle atrophy in 25.0% and both in 37.5%. Additionally, 40.6% of these studies indicated changes in myosin and actin proteins, with some showing a significant decrease in the myosin/actin ratio. More than a fifth (21.9%) of the studies reported changes in type I and/or type II muscle fibres, with 5 studies demonstrating significant damage to type II muscle fibres. The sepsis immobilisation model showed muscle weakness and atrophy in 40.0% of the studies and both features in 20%, with some studies reporting preferential myosin loss and a decrease in type II muscle fibers. For details, see Supplementary Table S3.
Muscular pathological changes were reported in 83.3% of the studies (n = 70/84), including muscle fibre morphology, cross-sectional muscle area (CSA), fibre diameters, myosin and/or actin protein, atrophic genes or proteins, and muscle type. The imaging methods utilised in the included studies were mostly HE and electron microscopy. A total 57.1% of the studies (n = 48/84) observed the changes via electrophysiological or electromyographic examinations of muscles, such as excitability, CMAP and muscular maximal twitch and tetanic force. Animal weight change was monitored in 48.9% of the studies (n = 41/84), while changes in muscle weight were described in 39.3% (n = 33/84). Daily behavioural changes in animals were assessed in 11.9% of the studies (n = 10/84), and animal grip strength was measured in 16.7% (n = 14/84). Further details are provided in Table 3.
TABLE 3
Details of outcome measurement.
CSA: cross-sectional area; MV: mechanical ventilation;/: none; MHC: myosin heavy chain; HE: HE, staining; N: the number of outcomes.
High animal mortality rate presents a significant challenge in ICU-AW animal research, with only 42.9% of the studies (n = 36/84) reporting animal mortality rates. Notably, the sepsis model predominantly reported mortality within 48Â h (25.6%, n = 11/43), with a mean mortality rate of 35.3%. In the ICU model, mortality was reported in only 21.9% of the studies (n = 7/32), predominantly within 24Â h, with a mean mortality rate of 24.6%. Only 71.4% of the studies (n = 60/84) utilised various life support treatments, including antibiotics, analgesia, fluid resuscitation, warmth maintenance, nutritional infusion and vital signs monitoring. Analgesia (n = 23), antibiotics (n = 23) and fluid resuscitation (n = 38) were the top three life support strategies used among the included studies.
Discussion
Animal experiments offer advantages in understanding the pathophysiological mechanisms of muscle dysfunction during critical illness and exploring intervention targets due to their reproducibility and environmental control. This is the first scoping review providing a comprehensive overview of current animal models of ICU-AW. It is based on a systematic retrieval and inclusion of all potential eligible studies, ensuring a rigorous and systematic approach to data analysis and synthesis, which offers a clear advantage over narrative reviews. The key findings are as follows: (i) There are currently no standard ICU-AW animal model. ICU animal models, which are commonly induced by MV and sepsis with other factors, were the most effective methods for inducing ICU-AW. (ii) The mortality rates of ICU models averaged 24.6%, though not all models reported mortality rates. (iii) The assessment and reporting of ICU-AW outcomes were often inadequate. (iv) Important risk factors, such as being elderly and female, were frequently overlooked, and issues related to trial design and sample estimation were inadequately addressed.
An ideal animal model for ICU-AW should be simple, cost-effective and capable of replicating its pathophysiological changes and risk factors (Zou et al., 2018). However, there are currently no standard ICU-AW animal models fully replicating the multiple risk factors and interventions present in ICU clinical settings, thus posing significant challenges for animal models (Yang et al., 2018). In our present review, ICU models, particularly those involving MV with various ICU-AW risk factors, are the most effective methods for inducing ICU-AW. In particular, we found that ICU models induced by MV with other risk factors showed muscle weakness and atrophy as well as a significant decrease in the myosin/actin ratio and type II muscle fibres, mimicking the pathological characteristic in human ICU-AW (Friedrich et al., 2015). However, implementing such models is challenging.
For example, rats and porcine induced with MV after deep anaesthesia or sedation, along with life support and other treatments, can effectively replicate the muscle wasting and weakness observed in humans with ICU-AW (Addinsall et al., 2022; Corpeno et al., 2014; Llano-Diez et al., 2011). However, the need for continuous 24-h monitoring and therapeutic interventions limits their practical use due to cost and labour demands (Lad et al., 2020). Ventilation durations also very significantly, lasting 18 h in mice (Tang et al., 2013), 5–8 days or 9–14 days in rats (Llano-Diez et al., 2011; Akkad et al., 2014; Renaud et al., 2013) and 5 days in pigs (Radell et al., 2004; Banduseela et al., 2013; Ochala et al., 2011a). While advancements in equipment miniaturisation have addressed many technical obstacles in establishing ICU procedures for rat or murine experiments (Kim, 2021), challenges remain, including the complexity of model development and management, high time and financial costs, high mortality rates and diagnostic difficulties. The limited applicability of heavy sedation and neuromuscular blocking agents, used in only a subset of ICU patients, also hinders the complete replication of the ICU clinical environment in these animal models (Zhu et al., 2019).
Additionally, the sepsis immobilisation model exhibits selective myosin filament loss, particularly in type II fibres, which aligns with ICU-AW pathology (Friedrich et al., 2015). Immobilised septic patients without MV actually represent a significant proportion of ICU patients. Animal models combining sepsis with limb immobilisation, also called sepsis-acquired muscle weakness (Latronico et al., 2023), have gained popularity due to their simplicity and ability to induce severe muscle weakness and atrophy (Ochala et al., 2011a). Thus, the sepsis with immobilisation model, coupled with appropriate resuscitation measures, offers a simpler and reliable approach for inducing muscle weakness and atrophy in critical illness animal models. It is especially suitable for laboratories lacking sufficient resources.
Although sepsis and disuse models were also used to explore ICU-AW in our review, none of the studies utilising these models found the typical pathological changes of ICU-AW ‘preferential myosin proteolysis’. Four studies on sepsis models reported decreases in myosin and actin content without preferential myosin proteolysis (Goossens et al., 2021; Witteveen et al., 2019). These findings support that sepsis-induced myopathy differs from the pathology of ICU-AW and cannot replicate ICU-AW accurately (Friedrich et al., 2015) and that the sepsis model is not recommended for inducing ICU-AW. Therefore, a standardised ICU-AW model must be developed in the near future to enhance reproducibility.
Our review revealed that the assessment and reporting of ICU-AW outcomes in studies were inadequate. It is crucial to evaluate whether animal models replicate the changes associated with ICU-AW to assess the validity of the models. Handgrip strength, electromyography or muscle biopsy is the primary diagnostic modality for identifying ICU-AW in patients (Latronico et al., 2023). While muscle atrophy is consistently assessed, about half of the studies involved electrophysiological parameters or grip strength. Specifically, 42.9% analysed the expression of atrophic genes or proteins, 20.2% discussed changes in myosin or actin and only 39.3% reported both weakness and atrophy. None of the studies evaluated if they could fully replicate the weakness and atrophy characteristics of CIP or CIM or distinguish the subtype of ICU-AW. Therefore, future research should adequately assess both muscle weakness and atrophy outcomes to distinguish the subtypes of ICU-AW.
The duration of intervention and timing of outcome assessment significantly influence the results, with considerable heterogeneity among the included studies (Ochala et al., 2011b). Only 42.9% reported outcomes at more than two time points. Diaphragm muscle samples were typically collected within 24Â h, while limb muscle sampling varied from 6Â h to 61 days post induction. Diaphragm fibre atrophy occurred after 12Â h of MV and worsened with prolonged ventilation, particularly within the first 72Â h (Schepens et al., 2015). Critically ill patients experienced a significant loss of nearly 2% of skeletal muscle per day during the first week of ICU admission (Latronico et al., 2023), with non-excitable muscle membranes observed in response to direct muscle stimulation (Bierbrauer et al., 2012). A complete sarcomere disruption was documented in 100% of patients with CIM 7 days after ICU discharges (Dos Santos et al., 2016). Variations in mortality rates and the timing of animal execution also affected outcome observations over time. In particular, ICU-AW often occurred 7 days after the onset of critical illness (Fazzini et al., 2023), and early deaths hindered the observation of muscle changes throughout the study period. Therefore, assessing muscle function and atrophy at different time points is essential for understanding the temporal contribution of ICU-AW development.
Female and older critically ill patients were found to be more susceptible to developing ICU-AW (Yang et al., 2023; Wu et al., 2022). Recent studies indicated that women experience muscle loss rates approximately 2.6–3.4 times higher than men (Wu et al., 2022), particularly in septic ICU patients (Zaragoza-GarcÃa et al., 2023). This gender disparity is associated with lower insulin sensitivity index and myocyte cross-sectional area (MCSA) of type IIa fibres in critically ill female patients (Engelhardt et al., 2022). Moreover, testosterone replacement therapy has shown potential in improving grip strength in patients with ICU-AW (Samuel and Swee, 2023). Interestingly, most included studies predominantly utilised male animals, while some failed to specify the animal gender. In addition, nearly half of the included studies did not report the animal age, with only 29.8% utilising adult animals and 2 studies involving older animals. This discrepancy underscores the importance of clearly defining the characteristics of animals in future research. Furthermore, prioritising the use of adult or older animals can better align experimental conditions with clinical observations in ICU patients.
Transparent reporting of research methods and findings, along with rigorous research design, is crucial for ensuring reproducibility (Percie du Sert et al., 2020). However, several quality issues were identified in the included preclinical studies. (i) Approximately 50% of the studies performed randomisation, but most RCT studies lacked clarity in their randomisation methods. (ii) None of the included studies reported using blinding, 27.4% of the studies failed to report the sample size, and none clarified whether the group sizes were similar at the start. Only one study estimated the sample size. (iii) The number of animals was unequal between the intervention and control groups. Mortality rate may account for the unequal group sizes. (iv) Essential information to assess risk of bias, such as allocation method, concealment methods and animal housing measures (e.g., environment, housing conditions, feeding and watering, health monitoring, handling and care), was rarely reported. These findings are consistent with previous studies (Percie du Sert et al., 2020; Guo et al., 2023). Although researchers may not always know whether mice or rats are from the same litter, after the induction of ICU-AW, it is expected that these animals will be housed individually. No study has addressed the clustering effects caused by hierarchies in the design and analysis, where measurements from the same cage or litter or cells from the same animal show greater similarity (Percie du Sert et al., 2020). Addressing such relationships in statistical analyses by incorporating or aggregating outcome variables to the cage, litter or animal level is crucial. These quality issues should be urgently considered to ensure accurate conclusions and guide future research effectively.
Our scoping review identified several shortcomings in previous animal studies of ICU-AW, including a lack of blinding, sample size estimation and randomisation, as well as limited reporting on animal characteristics, intervention and mortality, with a focus predominantly on male and young animals. To tackle these issues and improve future research, we recommend the following: (i) Standardized ICU-AW animal models that are easier to implement should be developed. Ensure that clinical scenarios are accurately replicated, establish clear criteria for successful model establishment, and create corresponding research design guidelines to enhance reproducibility. (ii) Scientific rigor in study design and transparent reporting should be improved using the 21 checklist items outlined in ARRIVE guidelines 2.0 (Percie du Sert et al., 2020) to increase reproducibility. (iii) Adult or elderly male and female animals should be considered to better reflect the clinical characteristics of ICU patients.
However, our scoping review have several limitations. Firstly, risk of bias assessments were not conducted due to the methodology of scoping reviews. This may lead to include some low-quality studies, potentionally affecting the robustness of the findings on ICU-AW animal models. Secondly, variations in intervention measures, animal species, study designs, and outcome measures contribute to substantial heterogeneity, which only allows for descriptive analysis rather than meta-analysis. Additionally, the data extraction process based on predefined categories may have oversimplified the information presented in the studies, potentially overlooking some valuable details.
Conclusion
In this scoping review, we outlined the current preclinical models of ICU-AW. While many preclinical models are used to study ICU-AW, the reporting of methodological details is often incomplete, compounding the limitations of the preclinical studies identified in this review. Although current ICU animal models can mimic the clinical situation and pathological changes of human ICU-AW patients, there is no standard model. MV animal models incorporating other ICU condition factors can simulate complex clinical scenarios well, but they are challenging to implement and manage. The sepsis immobilisation model offers a simpler alternative, especially for laboratories lacking sufficient resources. However, sepsis and disuse models cannot mimic the pathological characteristics of ICU-AW and are not recommended for inducing ICU-AW. Future preclinical studies aim to design a standard ICU-AW model that can enhance reproducibility and improve scientific rigour in identifying the mechanisms underlying ICU-AW.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.
Author contributions
QY: Data curation, Formal Analysis, Investigation, Writing–original draft, Writing–review and editing. JS: Data curation, Formal Analysis, Investigation, Writing–original draft. LY: Writing–original draft. YM: Writing–original draft. LX: Writing–original draft. XM: Writing–original draft. PX: Funding acquisition, Project administration, Resources, Supervision, Validation, Writing–original draft, Writing–review and editing. SC: Funding acquisition, Project administration, Resources, Supervision, Validation, Writing–original draft, Writing–review and editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation (Grant Nos. 82060359 and 82360382) of China.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys.2024.1423567/full#supplementary-material
References
1
AareS.OchalaJ.NormanH. S.RadellP.ErikssonL. I.GöranssonH.et al (2011). Mechanisms underlying the sparing of masticatory versus limb muscle function in an experimental critical illness model. Physiol. Genomics43 (24), 1334–1350. 10.1152/physiolgenomics.00116.2011
2
AckermannK. A.BostockH.BranderL.SchröderR.DjafarzadehS.TuchschererD.et al (2014). Early changes of muscle membrane properties in porcine faecal peritonitis. Crit. Care18 (4), 484. 10.1186/s13054-014-0484-2
3
AddinsallA. B.CaccianiN.BackéusA.HedströmY.ShevchenkoG.BergquistJ.et al (2022). Electrical stimulated GLUT4 signalling attenuates critical illness-associated muscle wasting. J. Cachexia Sarcopenia Muscle13 (4), 2162–2174. 10.1002/jcsm.12978
4
AiharaM.HiroseN.KatsutaW.SaitoF.MaruyamaH.HagiwaraH. (2017). A new model of skeletal muscle atrophy induced by immobilization using a hook-and-loop fastener in mice. J. Phys. Ther. Sci.29 (10), 1779–1783. 10.1589/jpts.29.1779
5
AkkadH.CorpenoR.LarssonL. (2014). Masseter muscle myofibrillar protein synthesis and degradation in an experimental critical illness myopathy model. PLoS One9 (4), e92622. 10.1371/journal.pone.0092622
6
AlamdariN.ToraldoG.AversaZ.SmithI.CastilleroE.RenaudG.et al (2012). Loss of muscle strength during sepsis is in part regulated by glucocorticoids and is associated with reduced muscle fiber stiffness. Am. J. Physiol. Regul. Integr. Comp. Physiol.303 (10), R1090–R1099. 10.1152/ajpregu.00636.2011
7
Al-NassanS.FujinoH. (2018). Exercise preconditioning attenuates atrophic mediators and preserves muscle mass in acute sepsis. Gen. Physiol. Biophys.37 (4), 433–441. 10.4149/gpb_2018001
8
BanduseelaV. C.ChenY. W.KultimaH. G.NormanH. S.AareS.RadellP.et al (2013). Impaired autophagy, chaperone expression, and protein synthesis in response to critical illness interventions in porcine skeletal muscle. Physiol. Genomics45 (12), 477–486. 10.1152/physiolgenomics.00141.2012
9
BanduseelaV. C.OchalaJ.ChenY. W.GöranssonH.NormanH.RadellP.et al (2009). Gene expression and muscle fiber function in a porcine ICU model. Physiol. Genomics39 (3), 141–159. 10.1152/physiolgenomics.00026.2009
10
BarnesB. T.ConfidesA. L.RichM. M.Dupont-VersteegdenE. E. (2015). Distinct muscle apoptotic pathways are activated in muscles with different fiber types in a rat model of critical illness myopathy. J. Muscle Res. Cell Motil.36 (3), 243–253. 10.1007/s10974-015-9410-8
11
BierbrauerJ.KochS.OlbrichtC.HamatiJ.LodkaD.SchneiderJ.et al (2012). Early type II fiber atrophy in intensive care unit patients with nonexcitable muscle membrane. Crit. Care Med.40 (2), 647–650. 10.1097/CCM.0b013e31823295e6
12
BloiseF. F.van der SpekA. H.SurovtsevaO. V.Ortiga-CarvalhoT. M.FliersE.BoelenA. (2016). Differential effects of sepsis and chronic inflammation on diaphragm muscle fiber type, thyroid hormone metabolism, and mitochondrial function. Thyroid26 (4), 600–609. 10.1089/thy.2015.0536
13
CallahanL. A.SupinskiG. S. (2014). Hyperglycemia-induced diaphragm weakness is mediated by oxidative stress. Crit. Care18 (3), R88. 10.1186/cc13855
14
CankayaliI.DoganY. H.SolakI.DemiragK.ErisO.DemirgorenS.et al (2007). Neuromuscular deterioration in the early stage of sepsis in rats. Crit. Care11 (1), R1. 10.1186/cc5139
15
CaoY. Y.WangZ.YuT.ZhangY.WangZ. H.LuZ. M.et al (2021). Sepsis induces muscle atrophy by inhibiting proliferation and promoting apoptosis via PLK1-AKT signalling. J. Cell Mol. Med.25 (20), 9724–9739. 10.1111/jcmm.16921
16
ChenJ.ChenX. Y.CongX. X.WangS.XuS. B.SunY. T.et al (2023). Cellular senescence implicated in sepsis-induced muscle weakness and ameliorated with metformin. Shock59 (4), 646–656. 10.1097/shk.0000000000002086
17
CorpenoR.DworkinB.CaccianiN.SalahH.BergmanH. M.RavaraB.et al (2014). Time course analysis of mechanical ventilation-induced diaphragm contractile muscle dysfunction in the rat. J. Physiol.592 (17), 3859–3880. 10.1113/jphysiol.2014.277962
18
CrowellK. T.LangC. H. (2021). Contractility and myofibrillar content in skeletal muscle are decreased during post-sepsis recovery, but not during the acute phase of sepsis. Shock55 (5), 649–659. 10.1097/shk.0000000000001555
19
De JongheB.SharsharT.LefaucheurJ. P.AuthierF. J.Durand-ZaleskiI.BoussarsarM.et al (2002). Paresis acquired in the intensive care unit: a prospective multicenter study. Jama288 (22), 2859–2867. 10.1001/jama.288.22.2859
20
Dos SantosC.HussainS. N.MathurS.PicardM.HerridgeM.CorreaJ.et al (2016). Mechanisms of chronic muscle wasting and dysfunction after an intensive care unit stay. A pilot study. Am. J. Respir. Crit. Care Med.194 (7), 821–830. 10.1164/rccm.201512-2344OC
21
ElkalawyH.SekharP.AbosenaW. (2023). Early detection and assessment of intensive care unit-acquired weakness: a comprehensive review. Acute Crit. Care38 (4), 409–424. 10.4266/acc.2023.00703
22
EngelhardtL. J.GrunowJ. J.WollersheimT.CarbonN. M.BalzerF.SprangerJ.et al (2022). Correction: Engelhardt et al. Sex-Specific Aspects of Skeletal Muscle Metabolism in the Clinical Context of Intensive Care Unit-Acquired Weakness. J. Clin. Med.11 (19), 5496. 10.3390/jcm11195496
23
FazziniB.MärklT.CostasC.BlobnerM.SchallerS. J.ProwleJ.et al (2023). The rate and assessment of muscle wasting during critical illness: a systematic review and meta-analysis. Crit. Care27 (1), 2. 10.1186/s13054-022-04253-0
24
FrickC. G.FinkH.GordanM. L.EckelB.MartynJ. A.BlobnerM. (2008). Chronic Escherichia coli infection induces muscle wasting without changing acetylcholine receptor numbers. Intensive Care Med.34 (3), 561–567. 10.1007/s00134-007-0852-3
25
FriedrichO.ReidM. B.Van den BergheG.VanhorebeekI.HermansG.RichM. M.et al (2015). The sick and the weak: neuropathies/myopathies in the critically ill. Physiol. Rev.95 (3), 1025–1109. 10.1152/physrev.00028.2014
26
Gayan-RamirezG.de PaepeK.CadotP.DecramerM. (2003). Detrimental effects of short-term mechanical ventilation on diaphragm function and IGF-I mRNA in rats. Intensive Care Med.29 (5), 825–833. 10.1007/s00134-003-1688-0
27
GonzalezA.AbrigoJ.AchiardiO.SimonF.Cabello-VerrugioC. (2022). Intensive care unit-acquired weakness: a review from molecular mechanisms to its impact in COVID-2019. Eur. J. Transl. Myol.32 (3), 10511. 10.4081/ejtm.2022.10511
28
GoossensC.WeckxR.DerdeS.Van HelleputteL.SchneidereitD.HaugM.et al (2021). Impact of prolonged sepsis on neural and muscular components of muscle contractions in a mouse model. J. Cachexia Sarcopenia Muscle12 (2), 443–455. 10.1002/jcsm.12668
29
GrunowJ. J.GanT.LewaldH.MartynJ. A. J.BlobnerM.SchallerS. J. (2023). Insulin signaling in skeletal muscle during inflammation and/or immobilisation. Intensive Care Med. Exp.11 (1), 16. 10.1186/s40635-023-00503-9
30
GuillonA.PreauS.AboabJ.AzabouE.JungB.SilvaS.et al (2019). Preclinical septic shock research: why we need an animal ICU. Ann. Intensive Care9 (1), 66. 10.1186/s13613-019-0543-6
31
GuoL. Y.KaustovL.BrennaC. T. A.PatelV.ZhangC.ChoiS.et al (2023). Cognitive deficits after general anaesthesia in animal models: a scoping review. Br. J. Anaesth.130 (2), e351–e360. 10.1016/j.bja.2022.10.004
32
HabrB.SalibaY.HajalJ.SmayraV.RiachyM.FaresN. (2020). Hydrocortisone mitigates ICU-AW by fine-tuning of muscle atrophic and hypertrophic signaling pathways in a sepsis model with limb immobilization. Life Sci.261, 118366. 10.1016/j.lfs.2020.118366
33
HahnA.KnyM.Pablo-TortolaC.TodirasM.WillenbrockM.SchmidtS.et al (2020). Serum amyloid A1 mediates myotube atrophy via Toll-like receptors. J. Cachexia Sarcopenia Muscle11 (1), 103–119. 10.1002/jcsm.12491
34
HermansG. V. den B. G. (2015). Clinical review: intensive care unit acquired weakness. Crit. Care19 (1), 274. 10.1186/s13054-015-0993-7
35
HillN. E.MurphyK. G.SaeedS.PhadkeR.ChambersD.WilsonD. R.et al (2017). Impact of ghrelin on body composition and muscle function in a long-term rodent model of critical illness. PLoS One12 (8), e0182659. 10.1371/journal.pone.0182659
36
HongliG.XiaohongW.ShaolinM.XiaopingC.XiaopingZ. (2012). Effects of mechanical ventilation on morphological properties and myosin heavy chain of diaphragm fibers in rats. J J. Xi'an Jiaot. Univ. Med. Ed.33, 324–328. 10.3969/j.issn.1671-8259.2012.03.015
37
HouY. C.PaiM. H.WuJ. M.YangP. J.LeeP. C.ChenK. Y.et al (2021). Protective effects of glutamine and leucine supplementation on sepsis-induced skeletal muscle injuries. Int. J. Mol. Sci.22 (23), 13003. 10.3390/ijms222313003
38
HouY. C.WuJ. M.ChenK. Y.WuM. H.YangP. J.LeeP. C.et al (2023). Glutamine and leucine administration attenuates muscle atrophy in sepsis. Life Sci.314, 121327. 10.1016/j.lfs.2022.121327
39
IntisoD.CentraA. M.BartoloM.GattaM. T.GravinaM.Di RienzoF. (2022). Recovery and long-term functional outcome in people with critical illness polyneuropathy and myopathy: a scoping review. BMC Neurol.22 (1), 50. 10.1186/s12883-022-02570-z
40
JiangY.WeiQ.LiuW.ChenQ.ChenX.YuanZ.et al (2022). Exploring the muscle metabolomics in the mouse model of sepsis-induced acquired weakness. Evid. Based Complement. Altern. Med.2022, 6908488. 10.1155/2022/6908488
41
JiaoG. Y.HaoL. Y.GaoC. E.ChenL.SunX. F.YangH. L.et al (2013). Reduced DHPRα1S and RyR1 expression levels are associated with diaphragm contractile dysfunction during sepsis. Muscle Nerve48 (5), 745–751. 10.1002/mus.23805
42
JudeB.TissierF.DubourgA.DroguetM.CastelT.LéonK.et al (2020). TGF-Β pathway inhibition protects the diaphragm from sepsis-induced wasting and weakness in rat. Shock53 (6), 772–778. 10.1097/shk.0000000000001393
43
KimC. (2021). Evolution of advanced miniaturization for active implantable medical devices. Nano-Bio- Electron. Photonic MEMS Packag., 407–415. 10.1007/978-3-030-49991-4_17
44
KressJ. P.HallJ. B. (2014). ICU-acquired weakness and recovery from critical illness. N. Engl. J. Med.371 (3), 287–288. 10.1056/NEJMc1406274
45
KutzL.ZhouT.ChenQ.ZhuH. (2023). A surgical approach to hindlimb suspension: a mouse model of disuse-induced atrophy. Methods Mol. Biol.2597, 1–9. 10.1007/978-1-0716-2835-5_1
46
LadH.SaumurT. M.HerridgeM. S.Dos SantosC. C.MathurS.BattJ.et al (2020). Intensive care unit-acquired weakness: not just another muscle atrophying condition. Int. J. Mol. Sci.21 (21), 7840. 10.3390/ijms21217840
47
LaitanoO.PindadoJ.ValeraI.SpradlinR. A.MurrayK. O.VillaniK. R.et al (2021). The impact of hindlimb disuse on sepsis-induced myopathy in mice. Physiol. Rep.9 (14), e14979. 10.14814/phy2.14979
48
LatronicoN.RasuloF. A.EikermannM.PivaS. (2023). Illness weakness, polyneuropathy and myopathy: diagnosis, treatment, and long-term outcomes. Crit. Care27 (1), 439. 10.1186/s13054-023-04676-3
49
Le DinhM.CarreiraS.ObertJ.Gayan-RamirezG.RiouB.BeuvinM.et al (2018). Prolonged mechanical ventilation worsens sepsis-induced diaphragmatic dysfunction in the rat. PLoS One13 (8), e0200429. 10.1371/journal.pone.0200429
50
LiL. F.YuC. C.HuangH. Y.WuH. P.ChuC. M.HuangC. Y.et al (2021). Suppression of hypoxia-inducible factor 1 α by low-molecular-weight heparin mitigates ventilation induced diaphragm dysfunction in a murine endotoxemia model. Int. J. Mol. Sci.22 (4), 1702. 10.3390/ijms22041702
51
LiX.SunB.LiJ.YeW.LiM.GuanF.et al (2023). Sepsis leads to impaired mitochondrial calcium uptake and skeletal muscle weakness by reducing the micu1:mcu protein ratio. S hock60 (5), 698–706. 10.1097/shk.0000000000002221
52
LiaoW. C.ChenY. H.LiH. Y.WangT. T.LanP.PanK. H.et al (2018). Diaphragmatic dysfunction in sepsis due to severe acute pancreatitis complicated by intra-abdominal hypertension. J. Int. Med. Res.46 (4), 1349–1357. 10.1177/0300060517747163
53
LiuH.PanD.LiP.WangD.XiaB.ZhangR.et al (2023). Loss of ZBED6 protects against sepsis-induced muscle atrophy by upregulating DOCK3-mediated RAC1/PI3K/AKT signaling pathway in pigs. Adv. Sci. (Weinh)10 (29), e2302298. 10.1002/advs.202302298
54
LiuL.LiT. M.LiuX. R.BaiY. P.LiJ.TangN.et al (2019). MicroRNA-140 inhibits skeletal muscle glycolysis and atrophy in endotoxin-induced sepsis in mice via the WNT signaling pathway. Am. J. Physiol. Cell Physiol.317 (2), C189-C199–c199. 10.1152/ajpcell.00419.2018
55
LiuL.MinS.LiW.WeiK.LuoJ.WuG.et al (2014). Pharmacodynamic changes with vecuronium in sepsis are associated with expression of α 7- and γ -nicotinic acetylcholine receptor in an experimental rat model of neuromyopathy. Br. J. Anaesth.112 (1), 159–168. 10.1093/bja/aet253
56
Llano-DiezM.ChengA. J.JonssonW.IvarssonN.WesterbladH.SunV.et al (2016). Impaired Ca(2+) release contributes to muscle weakness in a rat model of critical illness myopathy. Crit. Care20 (1), 254. 10.1186/s13054-016-1417-z
57
Llano-DiezM.GustafsonA. M.OlssonC.GoranssonH.LarssonL. (2011). Muscle wasting and the temporal gene expression pattern in a novel rat intensive care unit model. BMC Genomics12, 602. 10.1186/1471-2164-12-602
58
MateckiS.JungB.SaintN.ScheuermannV.JaberS.LacampagneA. (2017). Respiratory muscle contractile inactivity induced by mechanical ventilation in piglets leads to leaky ryanodine receptors and diaphragm weakness. J. Muscle Res. Cell Motil.38 (1), 17–24. 10.1007/s10974-017-9464-x
59
MengmengW. (2017). Alterations in calcium concentration and DHPR, RyR on diaphragm dysfunction in a rat model of sepsis. Liaoning, China: China Medical University. Doctor.
60
MrozekS.JungB.PetrofB. J.PaulyM.RobergeS.LacampagneA.et al (2012). Rapid onset of specific diaphragm weakness in a healthy murine model of ventilator-induced diaphragmatic dysfunction. Anesthesiology117 (3), 560–567. 10.1097/ALN.0b013e318261e7f8
61
NakanishiN.OnoY.MiyazakiY.MoriyamaN.FujiokaK.YamashitaK.et al (2022). Sepsis causes neutrophil infiltration in muscle leading to muscle atrophy and weakness in mice. Front. Immunol.13, 950646. 10.3389/fimmu.2022.950646
62
NardelliP.KhanJ.PowersR.CopeT. C.RichM. M. (2013). Reduced motoneuron excitability in a rat model of sepsis. J. Neurophysiol.109 (7), 1775–1781. 10.1152/jn.00936.2012
63
NardelliP.VincentJ. A.PowersR.CopeT. C.RichM. M. (2016). Reduced motor neuron excitability is an important contributor to weakness in a rat model of sepsis. Exp. Neurol.282, 1–8. 10.1016/j.expneurol.2016.04.020
64
OchalaJ.AhlbeckK.RadellP. J.ErikssonL. I.LarssonL. (2011a). Factors underlying the early limb muscle weakness in acute quadriplegic myopathy using an experimental ICU porcine model. PLoS One6 (6), e20876. 10.1371/journal.pone.0020876
65
OchalaJ.GustafsonA. M.DiezM. L.RenaudG.LiM.AareS.et al (2011c). Preferential skeletal muscle myosin loss in response to mechanical silencing in a novel rat intensive care unit model: underlying mechanisms. J. Physiol.589 (Pt 8), 2007–2026. 10.1113/jphysiol.2010.202044
66
OchalaJ.RenaudG.Llano DiezM.BanduseelaV. C.AareS.AhlbeckK.et al (2011b). Diaphragm muscle weakness in an experimental porcine intensive care unit model. PLoS One6 (6), e20558. 10.1371/journal.pone.0020558
67
OndaA.KonoH.JiaoQ.AkimotoT.MiyamotoT.SawadaY.et al (2016). New mouse model of skeletal muscle atrophy using spiral wire immobilization. Muscle Nerve54 (4), 788–791. 10.1002/mus.25202
68
OnoY.MaejimaY.SaitoM.SakamotoK.HoritaS.ShimomuraK.et al (2020). TAK-242, a specific inhibitor of Toll-like receptor 4 signalling, prevents endotoxemia-induced skeletal muscle wasting in mice. Sci. Rep.10 (1), 694. 10.1038/s41598-020-57714-3
69
OnoY.SaitoM.SakamotoK.MaejimaY.MisakaS.ShimomuraK.et al (2022). C188-9, a specific inhibitor of STAT3 signaling, prevents thermal burn-induced skeletal muscle wasting in mice. Front. Pharmacol.13, 1031906. 10.3389/fphar.2022.1031906
70
OwenA. M.PatelS. P.SmithJ. D.BalasuriyaB. K.MoriS. F.HawkG. S.et al (2019). Chronic muscle weakness and mitochondrial dysfunction in the absence of sustained atrophy in a preclinical sepsis model. Elife8, e49920. 10.7554/eLife.49920
71
Percie du SertN.HurstV.AhluwaliaA.AlamS.AveyM. T.BakerM.et al (2020). The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. Br. J. Pharmacol.177 (16), 3617–3624. 10.1111/bph.15193
72
PierreA.BourelC.FavoryR.BrassartB.WalletF.DaussinF. N.et al (2023). Sepsis-like energy deficit is not sufficient to induce early muscle fiber atrophy and mitochondrial dysfunction in a murine sepsis model. Biol. (Basel).12 (4), 529. 10.3390/biology12040529
73
PivaS.FagoniN.LatronicoN. (2019). Intensive care unit-acquired weakness: unanswered questions and targets for future research. F1000Res8. 10.12688/f1000research.17376.1
74
PreauS.AmblerM.SigurtaA.KleymanA.DysonA.HillN. E.et al (2019). Protein recycling and limb muscle recovery after critical illness in slow- and fast-twitch limb muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol.316 (5), R584-R593–r593. 10.1152/ajpregu.00221.2018
75
RadellP.EdströmL.StiblerH.ErikssonL. I.AnsvedT. (2004). Changes in diaphragm structure following prolonged mechanical ventilation in piglets. Acta Anaesthesiol. Scand.48 (4), 430–437. 10.1111/j.1399-6576.2004.00352.x
76
RadellP. J.RemahlS.NicholsD. G.ErikssonL. I. (2002). Effects of prolonged mechanical ventilation and inactivity on piglet diaphragm function. Intensive Care Med.28 (3), 358–364. 10.1007/s00134-002-1207-8
77
RadiganK. A.NicholsonT. T.WelchL. C.ChiM.AmarelleL.AnguloM.et al (2019). Influenza A virus infection induces muscle wasting via IL-6 regulation of the E3 ubiquitin ligase atrogin-1. J. Immunol.202 (2), 484–493. 10.4049/jimmunol.1701433
78
RenaudG.Llano-DiezM.RavaraB.GorzaL.FengH. Z.JinJ. P.et al (2013). Sparing of muscle mass and function by passive loading in an experimental intensive care unit model. J. Physiol.591 (5), 1385–1402. 10.1113/jphysiol.2012.248724
79
RocheteauP.ChatreL.BriandD.MebarkiM.JouvionG.BardonJ.et al (2015). Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy. Nat. Commun.6, 10145. 10.1038/ncomms10145
80
RossignolB.GueretG.PennecJ. P.MorelJ.RannouF.Giroux-MetgesM. A.et al (2008). Effects of chronic sepsis on contractile properties of fast twitch muscle in an experimental model of critical illness neuromyopathy in the rat. Crit. Care Med.36 (6), 1855–1863. 10.1097/CCM.0b013e318176106b
81
SamuelG. S.SweeD. S. (2023). Use of testosterone replacement therapy in the rehabilitation of patients with intensive care unit-associated weakness and hospital-associated deconditioning: the Singapore General Hospital rehabilitation experience. Singap. Med. J.0, 0. 10.4103/singaporemedj.SMJ-2021-307
82
SapraH. (2021). Intensive care unit-acquired weakness: a frequent but under-recognized threat. Indian J. Crit. Care Med.25 (9), 965–966. 10.5005/jp-journals-10071-23990
83
SchepensT.VerbruggheW.DamsK.CorthoutsB.ParizelP. M.JorensP. G. (2015). The course of diaphragm atrophy in ventilated patients assessed with ultrasound: a longitudinal cohort study. Crit. Care19, 422. 10.1186/s13054-015-1141-0
84
SchmittR. E.DasguptaA.Arneson-WissinkP. C.DattaS.DucharmeA. M.DolesJ. D. (2023). Muscle stem cells contribute to long-term tissue repletion following surgical sepsis. J. Cachexia Sarcopenia Muscle14 (3), 1424–1440. 10.1002/jcsm.13214
85
ShanelyR. A.ZergerogluM. A.LennonS. L.SugiuraT.YimlamaiT.EnnsD.et al (2002). Mechanical ventilation-induced diaphragmatic atrophy is associated with oxidative injury and increased proteolytic activity. Am. J. Respir. Crit. Care Med.166 (10), 1369–1374. 10.1164/rccm.200202-088OC
86
ShimataniT.ShimeN.NakamuraT.OhshimoS.HotzJ.KhemaniR. G. (2019). Neurally adjusted ventilatory assist mitigates ventilator-induced diaphragm injury in rabbits. Respir. Res.20 (1), 293. 10.1186/s12931-019-1265-x
87
SupinskiG. S.WangL.SchroderE. A.CallahanL. A. P. (2020a). Taurine administration ablates sepsis induced diaphragm weakness. Respir. Physiol. Neurobiol.271, 103289. 10.1016/j.resp.2019.103289
88
SupinskiG. S.WangL.SchroderE. A.CallahanL. A. P. (2020b). SS31, a mitochondrially targeted antioxidant, prevents sepsis-induced reductions in diaphragm strength and endurance. J. Appl. Physiol.128 (3), 463–472. 10.1152/japplphysiol.00240.2019
89
SupinskiG. S.WangL.SongX. H.MoylanJ. S.CallahanL. A. (2014). Muscle-specific calpastatin overexpression prevents diaphragm weakness in cecal ligation puncture-induced sepsis. J. Appl. Physiol.117 (8), 921–929. 10.1152/japplphysiol.00975.2013
90
TangH.LeeM.KhuongA.WrightE.ShragerJ. B. (2013). Diaphragm muscle atrophy in the mouse after long-term mechanical ventilation. Muscle Nerve48 (2), 272–278. 10.1002/mus.23748
91
TriccoA. C.LillieE.ZarinW.O'BrienK. K.ColquhounH.LevacD.et al (2018). PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann. Intern Med.169 (7), 467–473. 10.7326/M18-0850
92
VankrunkelsvenW.DerdeS.GunstJ.Vander PerreS.DeclerckE.PauwelsL.et al (2022). Obesity attenuates inflammation, protein catabolism, dyslipidaemia, and muscle weakness during sepsis, independent of leptin. J. Cachexia Sarcopenia Muscle13 (1), 418–433. 10.1002/jcsm.12904
93
VankrunkelsvenW.ThiessenS.DerdeS.VervoortE.DereseI.PintelonI.et al (2023). Development of muscle weakness in a mouse model of critical illness: does fibroblast growth factor 21 play a role?Skelet. Muscle13 (1), 12. 10.1186/s13395-023-00320-4
94
WangC.LiuY.ZhangY.WangD.XuL.LiZ.et al (2023). Targeting NAT10 protects against sepsis-induced skeletal muscle atrophy by inhibiting ROS/NLRP3. Life Sci.330, 121948. 10.1016/j.lfs.2023.121948
95
WangJ.WuT. (2020). Testosterone improves muscle function of the extensor digitorum longus in rats with sepsis. Bosci Rep.40 (2), BSR20193342. 10.1042/bsr20193342
96
WangW.XuC.MaX.ZhangX.XieP. (2020). Intensive care unit-acquired weakness: a review of recent progress with a look toward the future. Front. Med. (Lausanne)7, 559789. 10.3389/fmed.2020.559789
97
WeckxR.GoossensC.DerdeS.PauwelsL.Vander PerreS.Van den BergheG.et al (2022). Efficacy and safety of ketone ester infusion to prevent muscle weakness in a mouse model of sepsis-induced critical illness. Sci. Rep.12 (1), 10591. 10.1038/s41598-022-14961-w
98
WieskeL.HarmsenR. E.SchultzM. J.HornJ. (2011). Is critical illness neuromyopathy and duration of mechanical ventilation decreased by strict glucose control?Neurocrit Care14 (3), 475–481. 10.1007/s12028-011-9507-x
99
WitteveenE.HooglandI. C.WieskeL.WeberN. C.VerhammeC.SchultzM. J.et al (2016). Assessment of intensive care unit-acquired weakness in young and old mice: an E. coli septic peritonitis model. Muscle Nerve53 (1), 127–133. 10.1002/mus.24711
100
WitteveenE.WieskeL.MandersE.VerhammeC.OttenheijmC. A. C.SchultzM. J.et al (2019). Muscle weakness in a S. pneumoniae sepsis mouse model. Ann. Transl. Med.7 (1), 9. 10.21037/atm.2018.12.45
101
WuR. Y.SungW. H.ChengH. C.YehH. J. (2022). Investigating the rate of skeletal muscle atrophy in men and women in the intensive care unit: a prospective observational study. Sci. Rep.12 (1), 16629. 10.1038/s41598-022-21052-3
102
WuX.WolfS. E.WaltersT. J. (2010). Muscle contractile properties in severely burned rats. Burns36 (6), 905–911. 10.1016/j.burns.2010.02.003
103
YamadaT.HimoriK.TatebayashiD.YamadaR.AshidaY.ImaiT.et al (2018). Electrical stimulation prevents preferential skeletal muscle myosin loss in steroid-denervation rats. Front. Physiol.9, 1111. 10.3389/fphys.2018.01111
104
YangJ.MinS.XieF.ChenJ.HaoX.RenL. (2017). Electroacupuncture alleviates neuromuscular dysfunction in an experimental rat model of immobilization. Oncotarget8 (49), 85537–85548. 10.18632/oncotarget.20246
105
YangT.LiZ.JiangL.WangY.XiX. (2018). Risk factors for intensive care unit-acquired weakness: a systematic review and meta-analysis. Acta Neurol. Scand.138 (2), 104–114. 10.1111/ane.12964
106
YangZ.WangX.ChangG.CaoQ.WangF.PengZ.et al (2023). Development and validation of an intensive care unit acquired weakness prediction model: a cohort study. Front. Med. (Lausanne)10, 1122936. 10.3389/fmed.2023.1122936
107
YoshiharaI.KondoY.OkamotoK.TanakaH. (2023). Sepsis-associated muscle wasting: a comprehensive review from bench to bedside. Int. J. Mol. Sci.24 (5), 5040. 10.3390/ijms24055040
108
ZambelliV.Sigurtà A.RizziL.ZuccaL.DelvecchioP.BrescianiE.et al (2019). Angiotensin-(1-7) exerts a protective action in a rat model of ventilator-induced diaphragmatic dysfunction. Intensive Care Med. Exp.7 (1), 8. 10.1186/s40635-018-0218-x
109
ZandersL.KnyM.HahnA.SchmidtS.WundersitzS.TodirasM.et al (2022). Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting. J. Cachexia Sarcopenia Muscle13 (1), 713–727. 10.1002/jcsm.12867
110
Zaragoza-GarcÃaI.Arias-RiveraS.Frade-MeraM. J.MartÃJ. D.GallartE.San José-ArribasA.et al (2023). Enteral nutrition management in critically ill adult patients and its relationship with intensive care unit-acquired muscle weakness: a national cohort study. PLoS One18 (6), e0286598. 10.1371/journal.pone.0286598
111
ZhangJ. Y.WuJ.LiS. T.GongY. (2016). Lowered sarcoendoplasmic reticulum calcium uptake and diaphragmatic SERCA1 expression contribute to diaphragmatic contractile and relaxation dysfunction in septic rats. Nan Fang. Yi Ke Da Xue Xue Bao37 (4), 438–443. 10.3969/j.issn.1673-4254.2017.04.03
112
ZhangT.ZhaoxiaX.YaL.ZhongliZ.YuxiS.ChaoxS.et al (2019). Study on the establishment of ICU-acquired weakness model in rats with sepsis. J. South West Def. Med.29, 633–636. 10.3969/j.issn.1004-0188.2019.06.001
113
ZhengY.DaiH.ChenR.ZhongY.ZhouC.WangY.et al (2023). Endoplasmic reticulum stress promotes sepsis-induced muscle atrophy via activation of STAT3 and Smad3. J. Cell Physiol.238 (3), 582–596. 10.1002/jcp.30950
114
ZhuF.NairR. R.FisherE. M. C.CunninghamT. J. (2019). Humanising the mouse genome piece by piece. Nat. Commun.10 (1), 1845. 10.1038/s41467-019-09716-7
115
ZouW.LiuF.LiJ. (2018). Current status for animal models of intensive care unit acquired muscle weakness. Zhong Nan Da Xue Xue Bao Yi Xue Ban.43 (6), 691–696. 10.11817/j.issn.1672-7347.2018.06.018
Summary
Keywords
intensive care unit-acquired weakness, animal model, muscle weakness, muscle atrophy, scoping review
Citation
Yu Q, Song J, Yang L, Miao Y, Xie L, Ma X, Xie P and Chen S (2024) A scoping review of preclinical intensive care unit-acquired weakness models. Front. Physiol. 15:1423567. doi: 10.3389/fphys.2024.1423567
Received
26 April 2024
Accepted
23 September 2024
Published
02 October 2024
Volume
15 - 2024
Edited by
Claudia Camerino, University of Bari Aldo Moro, Italy
Reviewed by
Caspar Stephani, University Medical Center Göttingen, Germany
Yuko Ono, Kobe University, Japan
Updates
Copyright
© 2024 Yu, Song, Yang, Miao, Xie, Ma, Xie and Chen.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Peng Xie, pxie12345@126.com; Shaolin Chen, 30363284@qq.com
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.